USP7 and Miyoshi myopathy: For example, P5091, a small-molecule inhibitor of USP7, activates HDM2/p53/p21 signaling axis and exerts cytotoxicity in several multiple myeloma (MM) cell models, supporting future clinical investigations of USP7 inhibitors for the treatment of malignant hematological diseases21.